Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes drug ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co. (NYSE:LLY), disclosed the sale of shares worth approximately $183.6 million, according to recent filings. The transactions, which ...

It's next to impossible to predict what will happen in such a short period (by stock market standards). However, investors focused on the long game have nothing to fear. Eli Lilly remains an ...

Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, diabetes, immunology, neuroscience, and other therapies. The company is one ...

Eli Lilly and Company (NYSE:LLY) is an Indiana-based pharmaceutical company that manufactures and develops a wide range of medicines for serious ailments. The stock has performed exceptionally ...

David Jagielski (Eli Lilly): A forever stock you can put in your portfolio and not worry about is Eli Lilly. The healthcare company's robust financials, solid pipeline of drugs, and growing ...

The drugmaker is also an excellent stock for income-seeking investors. It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in lower-than ...